Nijmegen, The Netherlands – April 7, 2011 – Syntarga B.V., the emerging Antibody-
Drug Conjugate (ADC) company, announces today that it entered into a number of new
research collaboration agreements since its May 2010 press release. During this period,
collaboration agreements have been executed with multiple top-20 biopharmaceutical
companies, as well as with multiple biotech companies.
ADCs are being evaluated by the Company's collaborators in which the newest Syntarga
Linker-Drug chemistries are linked to collaborator antibodies. The Company has recently
presented biological data for its current ADC chemistries at international conferences.
“The exciting data generated for ADCs based on our optimized Linker-Drugs vis-à-vis
multiple established technologies, with regards to both efficacy and safety, have
triggered significant interest from top-tier (bio)pharma players. The growing package of
biological data for ADCs based on Syntarga technology against a variety of antigen
targets underscores the broad potential of the Company’s unique, proprietary
technologies.” said Dr. Vincent de Groot, Chief Executive Officer of Syntarga.
About Syntarga BV
Syntarga is a privately held biopharmaceutical company engaged in the discovery and
development of proprietary Antibody-Drug Conjugate technology and products for the
treatment of cancer. The Company's cutting-edge chemistry capabilities and unique
know-how have led to the creation of its antibody empowering Potent Payload
Technology. Syntarga is leveraging its proprietary technologies and expertise to generate
and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug
Conjugate products. For more information about Syntarga, visit its website at
Vincent de Groot, Ph.D., CLP T
CEO, Syntarga B.V. E
T: +31 24 3652 878
Source: Syntarga B.V.